Close Menu

NEW YORK – Molecular diagnostic firm Asuragen said Tuesday that its in vitro diagnostic test for spinal muscular atrophy received CE marking. 

The AmplideX SMA Plus Kit can help diagnose SMA and determine if asymptomatic carriers could pass the neuromuscular disease on to their children, the company said in a statement. The test quantifies the copy number of SMN1 and SMN2, the genes associated with the disease, and detects additional variants that can impact "silent carrier" status and overall disease prognosis.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The UK is investing £33.6 million into a controversial human SARS-CoV-2 challenge study, according to Reuters.

The Guardian reports that the UK COVID genomics consortium is monitoring mutations that are arising within circulating SARS-CoV-2 strains for any that may affect future vaccines.

Science reports that Max Planck and Nature have struck a deal for affiliated authors to publish papers that are accessible to the public as well as access Nature-branded journals.

In PNAS this week: genomic analysis of ancient animals from Tibet, oncoproteins tied to WEE1 kinase enzyme inhibitor response, and more.